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Abstract 
 
Rationale: The impact of COVID-19 on patients with Interstitial Lung Disease (ILD) has not 
been established. 
Objectives: To assess outcomes in patients with ILD hospitalized for COVID-19 versus those 
without ILD in a contemporaneous age, sex and comorbidity matched population. 
Methods: An international multicenter audit of patients with a prior diagnosis of ILD 
admitted to hospital with COVID-19 between 1 March and 1 May 2020 was undertaken and 
compared with patients, without ILD obtained from the ISARIC 4C cohort, admitted with 
COVID-19 over the same period. The primary outcome was survival. Secondary analysis 
distinguished IPF from non-IPF ILD and used lung function to determine the greatest risks of 
death. 
Measurements and Main Results: Data from 349 patients with ILD across Europe were 
included, of whom 161 were admitted to hospital with laboratory or clinical evidence of 
COVID-19 and eligible for propensity-score matching. Overall mortality was 49% (79/161) in 
patients with ILD with COVID-19. After matching ILD patients with COVID-19 had higher 
mortality (HR 1.60, Confidence Intervals 1.17-2.18 p=0.003) compared with age, sex and co-
morbidity matched controls without ILD. Patients with a Forced Vital Capacity (FVC) of <80% 
had an increased risk of death versus patients with FVC ≥80% (HR 1.72, 1.05-2.83). 
Furthermore, obese patients with ILD had an elevated risk of death (HR 2.27, 1.39−3.71).  
Conclusions: Patients with ILD are at increased risk of death from COVID-19, particularly 
those with poor lung function and obesity. Stringent precautions should be taken to avoid 
COVID-19 in patients with ILD.  
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Introduction 
Interstitial Lung Diseases (ILDs) represent a group of fibroinflammatory diseases affecting 
the alveolar interstitium of the lung. ILDs are characterized by alveolar damage and 
interstitial thickening and, if left untreated, lead to remorseless progression of 
breathlessness, cough and ultimately death from respiratory failure. The prevalence of ILDs 
in Europe is just under one per 1,000 people, with an annual incidence of approximately 20 
per 100,000 people (1). The commonest ILD is sarcoidosis, but one of the most severe ILD is 
Idiopathic Pulmonary Fibrosis (IPF), a high incidence of which is found in the UK (12 per 
100,000) (2, 3). IPF tends to affect older people with a mean age at diagnosis of 72 years. 
Men are more often affected than women. Furthermore, IPF is associated with diabetes 
mellitus type 2 (DMT2), hypertension (HT) and ischemic heart disease (IHD) (4, 5). People 
suffering from other ILDs (non-IPF ILD) tend to be younger, with a higher proportion of 
female sufferers, and often receive immunosuppressive therapy.  
All ILDs, most notably IPF, are characterized by acute exacerbations which have a 
particularly high mortality rate ranging from 35-70% (6). The precise cause of acute 
exacerbations is unknown, but they have been associated with thoracic surgical procedures 
and viral infections (6). Furthermore, an acute exacerbation is associated with the 
development of Acute Respiratory Distress Syndrome (ARDS) which carries a high mortality 
and morbidity. However, there is no consensus on treatment of ARDS in this group of 
patients, given that mechanical ventilation is the cornerstone of supportive therapy in non-
ILD patients (7). 
Infection with SARS-CoV-2 may lead to COVID-19, characterized by a severe viral pneumonia 
and ARDS in approximately 20% of patients admitted to hospital (8). Patients most at risk of 
severe COVID-19 include elderly males with comorbidities including DMT2, HT and IHD 
5 
 
(9,10) which are shared by patients with ILD, most notably IPF (5). To understand the risk to 
patients with ILD hospitalized with COVID-19 and therefore the potential benefits of self-
isolation during the pandemic, we undertook an international multicenter analysis of 
patients admitted to hospital between the 1 March and 1 May 2020 with COVID-19. We 
compared outcomes of patients with ILD with age, sex and comorbidity matched controls 
admitted with COVID-19 but without ILD, from a prospective UK cohort, the International 
Severe Acute Respiratory and Emerging Infection Consortium Coronavirus Clinical 
Characterisation Protocol (ISARIC4C CCP-UK).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
Methods 
Patients 
Physicians admitting patients with ILD throughout Europe were contacted through research 
networks, e-mail contacts and social media asked to identify all patients with a pre-existing 
diagnosis of ILD admitted to hospital between 1st March and 1st May 2020 during the first 
peak of the COVID-19 pandemic. Participating centers included tertiary ILD centers from 
Denmark, Germany, Italy, Republic of Ireland, Spain, and the UK and secondary care 
hospitals from Republic of Ireland and the UK to obtain as representative a European ILD 
population as possible. De-identified, unlinked data from individuals were included in the 
audit. Each contributing site was asked to identify individuals admitted to their local 
hospital. As SARS-CoV-2 was an emerging virus at the start of the pandemic and PCR testing 
has a high false negative rate, we defined  the diagnosis of COVID-19 based on a SARS-CoV-2 
positive polymerase chain reaction (PCR) swab and/or clinico-radiological diagnosis. Audit 
data was unified with the ISARIC4C CCP-UK database, with separate categorization of 
individuals who reported an existing chronic pulmonary disease. The ISARIC4C CCP-UK 
database is a prospective cohort study enrolling patients across the UK admitted to hospital 
with COVID-19. Patients admitted were identified by local investigators and followed up 
prospectively by clinical research staff. Detailed data on comorbidities, treatments received 
and outcomes were captured. The protocol is available at https://isaric.net/ccp/.  
 
Data on the presence of chronic lung disease, asthma and prescription data were collected 
for the comparator group. Based on these variables, patients with no previous respiratory 
disease were selected to most accurately estimate the change in hazard for patients with 
ILD. Significant comorbidities of diabetes (type 1 or type 2), hypertension, chronic heart 
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disease and malignancy, as well as immunomodulatory therapies, were recorded in both ILD 
audit data and the ISARIC database.  
 
Outcomes 
The primary outcome was In Hospital Mortality and other recorded outcomes were whether 
the patient was discharged or remained hospitalized at date of censoring (1 May 2020). 
Secondary outcomes included whether patients were ventilated, or received continuous 
positive airway pressure, other non-invasive ventilation, or high flow oxygen and were 
described as ‘enhanced respiratory support’.  Length of stay was recorded at date of death, 
discharge or date of censoring. All outcomes were recorded on a standardized case report 
form and entered without any identifiers directly onto a secure REDcap database. 
 
Ethics and Consent 
All data were entered by the Local Clinical Care Team in anonymized fashion without linkage 
to any patient identifiers in line with national and local audit guidance. In the UK Health 
Research Authority guidance was followed (https://www.hra.nhs.uk/covid-19-
research/guidance-using-patient-data/), and ethical approval was not required. Similar 
regulations applied in Denmark, Italy, Republic of Ireland. ISARIC4C CCP-UK received ethical 
approval from the South Central - Oxford C Research Ethics Committee in England (Ref: 
13/SC/0149), and by the Scotland A Research Ethics Committee (Ref: 20/SS/0028). Data 
from Spain was collected under the approval for observational studies (Ref UIC-IBU-2020-03 
and PR217/20). Data from Germany were collected under approval from ethics committee 
of the Medical faculty of the University of Heidelberg (ref S-186/2020). 
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Statistical Analysis 
Summary statistics are presented as frequencies and percentages for categorical data and 
mean (standard deviation (sd)) for normally distributed continuous data. Where continuous 
data were not normally distributed, the median (interquartile range [IQR]) was used. 
Differences in categorical data were compared using the Chi-square test, or Fisher’s exact 
test when expected counts were below 5 in any group. For continuous normally distributed 
2-group data, we compared differences using Welch’s T-test or Mann Whitney-U if data 
were not normally distributed. For multiple group comparisons of continuous data, we used 
Kruskall-Wallis tests. Data from the ILD dataset were matched in a 1:2 ratio with patients 
who did not have ILD from the ISARIC4C CCP-UK dataset using a nearest neighbor 
propensity-score matching algorithm. Patients in ISARIC4C CCP-UK with ILD were excluded 
to avoid double counting. We matched on confounders known to affect outcomes from 
COVID-19 disease including age, sex, diabetes, chronic cardiac disease, cancer, 
hypertension, and renal disease. Unmatched and matched populations were compared 
using standardized mean differences, plots and summary statistics. For survival analyses, 
time was taken as admission to death (in-hospital survival) using length of stay where date 
was not available. Discharge from hospital was considered an absorbing state (once 
discharged, patients were considered no longer at risk of death). Discharged patients were 
not censored and included in the risk set until the end of follow-up, thus discharge did not 
compete with death. We generated subclasses based on the propensity-score distance and 
included these as terms within Cox proportional hazards models, where estimates are 
presented as hazards ratios, alongside the corresponding 95% confidence interval (11).  Data 
were analyzed using R version 3.6.3 with tidyverse, matchit and finalfit packages. 
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Results 
Baseline Demographics 
Between March 1st and May 1st 2020, 349 patients with ILD were admitted to 37 hospitals 
throughout the UK and Europe (see supplementary Table 1). A total of 185 ILD patients had 
a diagnosis of COVID-19 and 161 were suitable for propensity-score matching (Figure 1). The 
majority of these 161 patients (114) had a positive SARS-CoV-2 PCR test, and only 47 were 
diagnosed clinically. Of these, 110 (68%) were male and the mean age was 73.2 (±11.5) 
years. The most common ILD was IPF, with 68 (42%) patients admitted to hospital (Table 1). 
During the same time period, 164 patients with ILD were admitted with an alternative non-
COVID diagnosis, of whom 69 (42.1%) had IPF. Overall the In Hospital Mortality (IHM) for 
patients with ILD and COVID-19 was 49% (79/161) compared with 17% (28/164) for patients 
with ILD admitted for other reasons. 
 
Effect of ILD on outcome from COVID-19 
After propensity-score matching, 161 patients with ILD were compared with 322 patients 
admitted to hospital between the 1st March and 1st May 2020 but without ILD, or other 
chronic lung disease (Table 1). There was significantly higher mortality in patients with ILD 
compared with non ILD patients (49% (79/161) vs 35% (114/322) p=0.013) and was 
associated with an increased risk of death in a matched adjusted analysis (HR 1.60 CI 1.17-
2.18 p=0.003). There was significantly higher mortality in patients with ILD compared with 
non ILD patients (figure 2), which was greatest in men and increased with age, which 
persisted for men after adjusting for age and comorbidity (adjusted HR 1.98, 95% CI 1.14 to 
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3.43, p = 0.015).  The risk of mortality was greatest in patients with IPF (HR 1.74, 95%CI 1.16 
to 2.60 p=0.007), but a higher mortality was also seen in non-IPF ILD (HR 1.50, 95%CI 1.02 to 
2.21 p=0.040; Figure 3a) when compared with matched patients without ILD. Of patients 
with non-IPF ILD, those with chronic hypersensitivity pneumonitis and rheumatoid ILD had 
the highest mortality (50% (7/14) and 40% (4/10) respectively), whilst those with sarcoidosis 
and connective tissue disease (excluding rheumatoid) related ILD had the lowest observed 
mortality (33% (3/9) and 23% (3/13) respectively). Overall, median length of stay in those 
who were still alive was not substantially different between patients without ILD (9 days 
[IQR 11])), compared with non-IPF ILD (10 days [IQR 8])) and IPF (10 days [IQR 8]) (p = 0.725) 
(Table 2). 
 
Predictors of outcome from COVID-19 
Obesity has been previously described to increase the risk of death from COVID-19. After 
obesity was included in the propensity score matching (129/161 ILD patients with data 
available, matched to 260 non-ILD patients), being obese and having ILD was significantly 
associated with an increased hazard of death from COVID-19 (adjusted HR 2.27, 95%CI 1.39 
to 3.71, p = 0.001; figure 3b), which was greater than the effect of obesity in non-ILD 
patients.  
To determine whether patients with more severe ILD had a greater risk of mortality with 
COVID-19, the last available lung function results prior to hospital admission were analyzed. 
For all ILD patients, the mean Forced Vital Capacity (FVC) in patients surviving COVID-19 was 
82.2% predicted compared with 76.8% predicted in patients who died (p=0.121). Similarly, 
the mean Diffusion coefficient of Carbon Monoxide (DLco) was 56.4% predicted in survivors 
compared with 49.6% in patients dying with COVID (p=0.072; Table 3). When the FVC was 
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dichotomized using the 80% predicted threshold between mild and moderate ILD, in line 
with UK prescribing policy for anti-fibrotic medication, the risk of mortality was significantly 
higher in patients with moderate or severe ILD (HR 1.72, 95% CI 1.05-2.83), compared with 
mild disease (Figure 3c). 
  
Ventilatory support for ILD patients with COVID-19 
Most patients with ILD (84%; 135/161) did not receive enhanced respiratory support which 
was similar to matched patients without ILD (79%; 254/322; Table 2). Significantly more 
patients who survived did not receive enhanced respiratory support (93%, 76/82) compared 
with those who died (75%; 59/79 p=0.015). Of the 26 patients receiving enhanced 
respiratory support 77% (20) died, including 83% (5/6) of matched patients with ILD 
receiving ventilation (Table 4). 
 
Effect of anti-fibrotic and immunosuppressive therapy on outcome from COVID-19. 
In patients with ILDs 106 were taking no immunosuppressants or anti-fibrotic of whom 50% 
died (53/106; Table 5). Almost a third of patients with IPF (20/68) were receiving anti-
fibrotic therapy at the time of admission. Seven patients were receiving pirfenidone and 13 
were receiving nintedanib. Of those receiving anti-fibrotic therapy, 50% (10/20) died.  
Where immunosuppressants were reported, corticosteroids were most frequently 
prescribed (45/55) followed by mycophenolate (17/55); overall 47% (26/55) of patients 
taking anti-fibrotics or immunosuppressants died. Significantly more patients with ILD 
received oral corticosteroids in hospital than patients without ILD (27.8% versus 9.9%; 
p<0.001) but there was no difference in outcome between those receiving corticosteroids 
(48.9% mortality (22/55)) and those who did not (48.7% mortality (57/117)). 
12 
 
 
 
Discussion 
Determining the risk of poor outcome in patients pre-existing conditions who acquire SARS-
CoV-2 infection is crucial to determine what mitigation measures are required in the 
community. Our study shows that patients with existing interstitial lung disease were at very 
high risk of death when hospitalized with COVID-19, especially if they have reduced prior 
lung function or obesity. Most died without being offered mechanical ventilation; in those 
who were ventilated, mortality was very high. 
 
Our observations were in keeping with other studies which have identified increasing age, 
comorbidities (Diabetes Mellitus, Ischemic Heart Disease, other non-ILD Chronic Pulmonary 
Diseases) and male sex as predictors of poor outcome in COVID-19 (9,12). Unfortunately, 
the risk for patients with ILD has not yet been quantified because patients with uncommon 
diseases often do not have their specific diagnostic information recorded in large 
observational studies or are often not accurately reported in administrative healthcare 
datasets. Despite the unknown risk of COVID-19 for patients with ILD, many patients chose 
to self-isolate and, therefore, there appeared to be apparent ‘protection’ from COVID-19 
observed to many ILD physicians around the world. To accurately understand the risk of 
COVID-19 and inform decision- and risk-matrices going forward, the European ILD 
community undertook an audit of hospitalized patients with ILD between the 1st March and 
1st May 2020 to coincide with the first peak of COVID-19 within Europe. These data 
represent the largest assessment of the impact of SARS-CoV-2 infection on patients with ILD 
to date. These data demonstrate that patients with ILD are at increased risk of death 
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following hospitalization for COVID-19 particularly elderly males, with poor lung function 
and obesity. It is notable that the risk of In Hospital Mortality from COVID-19 for patients 
with ILD is particularly associated with male sex and obesity. These risk factors are 
associated both with development of IPF, and mortality from COVID-19 in the general 
population, which may suggest synergy between shared mechanisms of pathogenesis (13). 
 
The role of viral infection promoting acute exacerbations of ILD has been investigated for a 
number of years without a definitive answer, which probably reflects the range of viruses 
studied, the number of patients needed to explore such a hypothesis, and more broadly the 
challenges studying acute exacerbations of ILD (14,15,16,17). These data confirm that 
patients with ILD are at increased risk of mortality from COVID-19 compared with a matched 
population without ILD and the risk is greatest for IPF consistent with a respiratory virus 
inducing acute exacerbations of ILD.  
 
Factors associated with poor prognosis in acute exacerbations of ILD include pulmonary 
fibrosis and poor lung function prior to admission and fibrotic ILDs (18,19,20,21). The data 
presented here, support these prior studies demonstrating that patients with a recorded 
FVC <80% predicted prior to admission had an increased mortality compared with those 
with an FVC >80%. Similarly, patients with fibrotic ILDs such as Chronic Hypersensitivity 
Pneumonitis had mortality rates comparable with IPF and higher than those with Sarcoid or 
Connective Tissue Disease associated ILD. Interestingly, obese patients with ILD had a 
substantially increased risk of mortality. This may reflect use of steroids in severe disease, 
although we do not favor this hypothesis as there was no apparent increased risk of death 
associated with corticosteroid use. Obesity may be due to limited activity in ILD patients, a 
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condition that leads to progressive reduction in exercise tolerance as it becomes more 
severe (22). Alternatively, and perhaps most intriguingly, it may lend support to the 
hypothesis that severe ILD is part of the ‘metabolic syndrome’ (23). 
 
This analysis also assessed respiratory support offered to patients hospitalized with ILD. In 
line with current practice and guidelines most patients did not receive any ventilatory 
support (7, 24). Most patients who survived did not require enhanced respiratory support 
such as High Flow Oxygen, Continuous Positive Airway Pressure or ventilation, and of those 
receiving enhanced respiratory support the majority died. These data continue to support 
the use of supportive care in preference to either non-invasive or invasive mechanical 
ventilation except in clearly defined cases such as predominantly inflammatory ILD or 
bridging to transplantation. 
 
This analysis has a number of strengths. It is the largest, international, multicenter study to 
assess the outcome of patients with Interstitial Lung Disease hospitalized with the 
respiratory infection SARS-Cov-2. Merging of the ILD Audit dataset with the ISARIC4C CCP-
UK dataset enabled accurate, contemporary propensity-score matching for a number of 
potential confounding factors to assess the risk from COVID-19 disease. This enabled an 
assessment of the risk to patients with ILD infected with SARS-CoV-2, facilitating evidence-
based mitigation strategies, such as self-isolation for this vulnerable group of patients. 
This study also has some potential weaknesses. Due to the retrospective nature of the data 
collection recall bias might have led to over-selection of severe cases of COVID-19 in 
patients with ILD, however, this is mitigated by the large number of centers participating in 
the audit. Similarly, because only hospitalized patients could be included, it is possible that a 
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large number of patients with ILD and COVID-19 were omitted and, therefore, the risk of 
COVID-19 could be over-stated. However, given the demographic associated with ILD we 
think this is unlikely. Also, the comparator group only included patients from the UK and 
some younger patients which could have led to residual confounding by geographical 
determinants of disease severity and treatment, however as 86% of ILD patients were 
recruited from UK we think this is unlikely to be a major source of confounding.  Although 
patients with ILD were less likely to receive invasive mechanical ventilation, this is more 
likely due to their severe respiratory disease, however there was insufficient detail in the 
audit data collection to match for COVID-19 severity based on admission severity scores or 
provide more granularity relating to the nature of respiratory support received. However, 
we did not observe any patterns across the groups which were likely to have an effect. 
Similarly, the propensity score matching will have helped to address any imbalances which 
are observed within the matching variables. 
 
The effect of obesity was assessed in the matched population suggesting an increased risk in 
patients without ILD, however in contrast with prior reports (9,25) no effect of obesity was 
observed in the control population. This reflects the limitations associated with recording 
obesity using inpatient data where obesity is not objectively measured as well as the 
relatively small numbers of patients used in the matching and the large amount of missing 
data relating to weight. Therefore, the data relating to obesity must be interpreted 
accordingly, but we believe as a modifiable risk factor it is important to highlight the risk of 
obesity in patients with ILD who might develop COVID-19. Finally, it was not possible to 
evaluate specific treatment effects, such as the use of anti-fibrotics, immunosuppressants or 
anti-viral therapies. The audit was undertaken in the early part of the pandemic when 
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Hydroxychloroquine (HCQ) and remdesivir were only available in the context of clinical 
trials. The UK Medicine Health Regulatory Agency (MHRA) did not approve remdesivir for 
use in the UK until 26 May 2020 and HCQ has been shown to have no effect on outcome in 
any circumstance of COVID-19 infection (26,27), therefore it is highly unlikely that the 
results are confounded by anti-viral therapy. Only a proportion of patients received anti-
fibrotics during their admission.  Furthermore, due to the unknown effect of anti-fibrotics, 
and concerns regarding immunosuppression on the clinical course of COVID-19 there is 
likely to be considerable confounding due to indication. There are both potential benefits 
(28,29) and harms associated with background therapy for ILD (30). With specific reference 
to corticosteroids our analysis did not show any effect on mortality in patients with ILD. 
Although the RECOVERY study demonstrated an overall beneficial effect of Dexamethasone 
in patients with COVID-19, there was considerable heterogeneity in the response (27), and it 
is not clear to what extent steroid choice, steroid dosing, steroid duration, or pre-COVID-19 
steroid therapy impact on outcome. However, it is reassuring from a safety perspective that 
there was no obvious signal suggesting harms associated with background therapy for ILD in 
patients with COVID-19, although, further study to evaluate the consequence of anti-fibrotic 
and immunomodulatory therapy in ILD are needed.  
 
In summary, these data demonstrate that patients with ILD, particularly those with fibrotic 
ILD are at higher risk of mortality from COVID-19 than patients without ILD. Furthermore, 
the risk is heightened in elderly males, those with obesity or poor lung function and we 
would recommend dietary advice in overweight patients. We also propose that patients 
with ILD, particularly severe fibrotic ILD, continue to be regarded as high risk of mortality 
from COVID-19 and follow national self-isolation guidelines for vulnerable individuals and be 
17 
 
prioritized for SARS-CoV-2 vaccination at such time as it becomes available. Finally, we 
believe these data demonstrate the importance of international collaboration to collect 
data to understand the consequences of emerging threats to patients with ILD. 
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Figure Legends 
Figure 1 Audit Flow Diagram showing patients recruited and flow to matching. 
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Figure 2 A) In Hospital Mortality with 95% confidence intervals for female ILD patients 
hospitalized with COVID-19 stratified by age compared with those without ILD.  B) In 
Hospital Mortality with 95% confidence intervals for male ILD patients hospitalized with 
COVID-19 stratified by age compared with those without ILD. 
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Figure 3 A) Effect of ILD on mortality following COVID-19 (Propensity Matched), B) effect of 
obesity and ILD (Propensity Matched) C) and effect of FVC on outcome in ILD patients only.  
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Table 1 – Patient Characteristics by ILD 
 
 Total N levels No ILD ILD p 
Total N (%)   322 (66.7) 161 (33.3)  
Age (years) 483 Mean (SD) 72.6 
(13.4) 
73.2 
(11.5) 
0.639* 
Age categories 483 <50 10 (3.1) 5 (3.1) 1.000 
  50-69 112 (34.8) 56 (34.8)  
  70-79 96 (29.8) 48 (29.8)  
  80+ 104 (32.3) 52 (32.3)  
Sex at Birth 483 Male 220 (68.3) 110 (68.3) 1.000 
ILD 483 Chronic 
Hypersensitivity 
Pneumonitis 
0 (0.0) 14 (8.7)  
  Connective 
Tissue Disease 
related ILD 
0 (0.0) 13 (8.1)  
  Idiopathic 
Pulmonary 
Fibrosis 
0 (0.0) 68 (42.2)  
  Other 0 (0.0) 47 (29.2)  
  Rheumatoid 
related ILD 
0 (0.0) 10 (6.2)  
  Sarcoidosis 0 (0.0) 9 (5.6)  
Chronic Cardiac 
Disease 
483 Yes 92 (28.6) 46 (28.6) 1.000 
Diabetes 483 Yes 98 (30.4) 49 (30.4) 1.000 
Malignant 
neoplasm  
483 Yes 56 (17.4) 28 (17.4) 1.000 
Obesity 419 Yes 23 (7.1) 45 (28.0) <0.001 
  (Missing) 32 (9.9) 32 (19.9)  
Hypertension 483 Yes 148 (46.0) 74 (46.0) 1.000 
Chronic kidney 
disease 
483 Yes 16 (5.0) 8 (5.0) 1.000 
Pirfenidone 483 Yes 0 (0.0) 7 (4.3)  
Nintedanib 483 Yes 0 (0.0) 13 (8.1)  
Corticosteroids 483 Yes 28 (8.7) 45 (28.0) <0.001 
 
ILD- Interstitial Lung Disease. SD – Standard Deviation. All test Chi-square unless indicated by * where Welch’s 
two sample t-test used. 
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Table 2: Outcomes by ILD 
 Total N levels No ILD ILD p 
Died 483 Died 114 (35.4) 79 (49.1) 0.013 
Respiratory 
Support 
483 
Unenhanced 
respiratory 
support* 
254 (78.9) 136 (84.5) 0.288 
  
Enhanced 
Respiratory 
Support 
39 (12.1) 20 (12.4)  
  Ventilation 29 (9.0) 6 (3.7)  
Length of stay 
for those alive 
290 Median (IQR) 9.0 (11.0) 10.0 (8.0) 0.725** 
IQR – Interquartile range. All test Chi-square unless indicated by *Standard flow-rate Oxygen supplementation 
not considered ‘enhanced’ respiratory support, CPAP and High Flow O2 considered enhanced respiratory 
support.  **where Kruskall Wallis used. 
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Table 3 – Lung function in ILD group by outcome 
label Total N  Alive Died p 
Forced Vital Capacity 147 Mean (SD) 2.7 (1.0) 2.6 (0.9) 0.372* 
Forced Vital Capacity, 
percentage of 
predicted 
151 Mean (SD) 82.2 (23.0) 76.8 (21.0) 0.135* 
Forced Vital Capacity, 
at 80% of predicted 
151 FVC < 80% 35 (42.7) 42 (60.9) 0.039 
  FVC > 80% 47 (57.3) 27 (39.1)  
Forced Vital Capacity, 
percentage of 
predicted 
151 <50% 7 (6.9) 4 (4.8) 0.070 
  50 to 80% 28 (27.7) 38 (45.8)  
  80 to 100% 33 (32.7) 17 (20.5)  
  Over 100% 14 (13.9) 10 (12.0)  
Diffusing capacity for 
carbon monoxide 
81 Mean (SD) 5.2 (3.4) 4.2 (1.9) 0.093* 
Diffusing capacity for 
carbon monoxide, 
percentage of 
predicted 
122 Mean (SD) 56.4 (19.4) 49.6 (21.6) 0.072* 
 
All ILD patients including those unmatched. SD – Standard Deviation. All tests Welch’s two sample t-test, 
unless indicated by * where Kruskall Wallis used.  
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Table 4: Use of Ventilation in patients with ILD by outcome 
 
 Total N  Alive Died p 
Respiratory Support 161 
Unenhanced respiratory 
support* 
76 (92.7) 59 (74.7) 0.015 
  
Enhanced Respiratory 
Support 
5 (6.0) 15 (23) 0.005 
  Ventilation 1 (1.2) 5 (3.8) 0.190 
      
All test Chi-square. *Standard flow-rate Oxygen supplementation not considered ‘enhanced’ respiratory 
support, CPAP and High Flow O2 considered enhanced respiratory support. Note a further 10 patients with ILD 
were ventilated but not included in the matched cohort, of those 6 survived. 
 
Table 5: Drugs received by patients with ILD in matched cohort (n=161) 
 levels Alive Died 
Received 
Immuno-
suppressants/ 
Anti-fibrotics 
Yes 29 (34.9) 26 (32.9) 
Methotrexate/ 
Azathioprine 
Yes 3 (3.6) 2 (1.3) 
Nintedanib Yes 9 (10.8) 4 (5.1) 
Pirfenidone* Yes 1 (1.2) 6 (7.6) 
Mycophenolate Yes 10 (12.0) 7 (8.9) 
Corticosteroid Yes 23 (27.7) 22 (27.8) 
*2 further patients received pirfenidone and survived but were not included in matched 
cohort.  
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Supplementary Table 1 
COUNTRY NUMBER PERCENTAGE 
UK 299 86 
REPUBLIC 
OF 
IRELAND 
11 3 
SPAIN 27 7.5 
GERMAN 5 1.5 
ITALY 5 1.5 
DENMARK <3 <1 
 
 
Supplementary Table 2 
label ‘Other’ ILD diagnoses n 
Other ILD Details Age-related ILD/presbyotic lung <3  
 ANCA vasculitis  <3 
 asbestosis 5  
 Autoimmune Pneumonitis 5  
 Chronic eosinophilic pneumonia <3 
 Combined Emphysema and Pulmonary Fibrosis 7  
 Desquamative Intestitial Pneumonia <3 
 Non-Specific Interstitial Pneumonia 10  
 Organising Pneumonia <3  
 PPFE <3 
 smoking related ILD <3 
 Unclassifiable ILD 11 
 
 
 
Supplemental Figure  
 
Figure S1 Balance Plots 
Distribution of differences across ILD groups by matching variable. Propensity score 
matching normalised standardized mean differences across the treatment groups, with 
observed differences before matching not being present after. 
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Figure S2 Impact of sex, and co-morbidity on outcomes of COVID-19 in ILD] 
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